Skip to content

LEDA Pharma

Active Private limited companyfounded 2010active for 16 yearsDorpsstraat 29, 3360 BierbeekKBO/BCE: BE 0825.107.833 subsidiary of

Board

1 director, last change in 2020
Director, permanent representative
appointed by deed of 01-07-2020 term without a fixed end
also on the board of 1 other company
listed in the 2025 annual accounts, filed on 31-07-2026
Permanent representatives 1
Permanent representative, for
appointed by deed of 01-07-2020

Office holders in the KBO →

Mandates through the years

4 names, the dashed line is today

Director

Manager

Manager

Manager
BoardEarliermandate already running before its first mentionend not dated
Mandates as a list
    • Director, appointed by deed of 01-07-2020, still in office
    • Manager, appointed by deed of 21-06-2013, until 01-07-2020
    • Manager, until 31-12-2012
    • Manager, appointed by deed of 12-03-2018, until 01-07-2020
    • Manager, appointed by deed of 20-02-2014, until 31-12-2017
    • Manager, appointed by deed of 20-02-2014, no longer listed in the 2025 annual accounts

Control

Parent
Equity €428,624
Profit €115,380 in 2025 (profit €96,648 in 2024)
Checked score
100%
This company
LEDA Pharma
Equity -€51,021
Profit €6,990 in 2025

Further up the chain consolidates

and 1 other shareholder

Capital

Contribution
€6,200
Source
deed of 01-07-2020

Owners through the years

as the annual accounts name them
100%
consolidates until 2016
Owners as a list
    • 2024 to 2025: 100%

Source: parent in its own accounts, lists of holdings in the owners' accounts

Articles of association

deed of 01-07-2020 (in Dutch)
Board ruleThese rules set how the board is made up, meets and takes decisions.
At least 1 director
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
First Monday of June at 20:30

Shareholders

2 owners

Owners 2

  • parent
    Equity €428,624 Profit of €115,380 in 2025 (profit of €96,648 in 2024) Checked score
    Sourceaccounts 2025
    100%
  • consolidating parent
    Equity €1.5m Profit of €90,551 in 2025 (profit of €163,035 in 2024) Checked score
    consolidates

Next steps